Revenues Increased 7.4%; Net Income of $.05 per Diluted Share
FARMINGDALE, N.Y., Nov. 13 /PRNewswire-FirstCall/ -- Misonix, Inc.
(Nasdaq: MSON), a developer of minimally invasive ultrasonic medical device
technology, which in Europe is used for the ablation of tumors and
worldwide for other acute health conditions, today reported financial
results for its fiscal year 2009 first quarter ended September 30, 2008.
Michael A. McManus, Jr., President and Chief Executive Officer, and Richard
Zaremba, Senior VP and Chief Financial Officer, will host a conference call
at 4:30 p.m. Eastern on Thursday, November 13, 2008 to discuss the
Company's first quarter financial results.
-- Revenues increased 7.4% to $11.3 million
-- Reported net income of $320,000 or $.05 per diluted share
-- The Company reported the following operational achievements:
-- Entered a new, three year exclusive distribution agreement in Russia
for the Sonablate 500(R)
-- Received second FDA approval for the Sonablate 600(R) Soft Tissue
-- Entered a new two year exclusive distribution agreement in Czech
Republic for Sonastar(TM), SonicOne(R) and BoneScalpel(TM)
Revenues for the three months ended September 30, 2008 were $11.3
million, a 7.4% increase, when compared with revenues of $10.5 million for
the same period in fiscal 2008. The increase is due to a $621,000 increase
in sales of laboratory and scientific products to $5.9 million and a
$154,000 increase in medical device products sales to $5.4 million. The
increase in sales of medical device products is due to a $173,000 increase
in therapeutic medical device products partially offset by a $1
|SOURCE Misonix, Inc.|
Copyright©2008 PR Newswire.
All rights reserved